Low-level laser therapy may help uninfected cells but has different effects on coronavirus-infected cells.
February 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.
December 2023 in “Journal of Cosmetic Dermatology” Baricitinib effectively and safely improves hair growth in patients with severe alopecia areata.
November 2023 in “Journal of Cosmetic Dermatology” Tofacitinib is effective and has minor, reversible side effects for treating severe hair loss in Iran.
November 2023 in “Вопросы современной педиатрии” Genetic testing can diagnose hair loss linked to DSG4 gene variants.
November 2023 in “Journal of Investigative Dermatology” The study identified key immune cell differences between mild and severe alopecia areata.
October 2023 in “Journal of the Endocrine Society” Joint replacement surgery normalized high alkaline phosphatase levels in a patient with severe osteoarthritis.
September 2023 in “Journal of the American Academy of Dermatology” Risankizumab effectively treats and maintains skin clearance in moderate-to-severe psoriasis.
September 2023 in “Journal of The American Academy of Dermatology” Reducing the dose of Baricitinib to 2mg led to a loss of hair regrowth benefits in nearly half of the patients by Week-104.
July 2023 in “Anais Brasileiros de Dermatologia” Mesalazine showed limited effectiveness in treating children with severe alopecia areata.
June 2023 in “Dermatology and Therapy” Using fractional CO2 laser with halometasone cream works better for chronic hand eczema than just the cream, improving symptoms and quality of life with fewer relapses.
January 2023 in “Annals of dermatology/Annals of Dermatology” A substance called miR-1246 may help treat severe hair loss by reducing certain immune cell activities.
October 2021 in “Case Reports in Veterinary Medicine” The dog died from myxedema coma linked to severe atherosclerosis and thyroid issues.
June 2020 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” Researchers found a specific T cell receptor linked to severe drug reactions like Stevens-Johnson syndrome when patients take carbamazepine.
January 2020 in “Indian Journal of Forensic Medicine & Toxicology” Oral cyclosporine is an effective and safe treatment for severe alopecia areata.
December 2013 in “American journal of transplantation” The patient improved after antiviral treatment for a viral infection.
May 2011 in “Value in Health” CP-690,550 significantly reduced itching in patients with moderate-to-severe plaque psoriasis.
November 2022 in “Clinical, Cosmetic and Investigational Dermatology” The combined treatment for hair loss is effective, easy to use, and has mild side effects.
139 citations
,
December 2020 in “Cell Stem Cell” Male hormones affect COVID-19 severity and certain drugs targeting these hormones could help reduce the risk.
35 citations
,
January 2022 in “Clinical Infectious Diseases” Healthcare workers with COVID-19 reported more long-term symptoms, and physical activity may help reduce some of these symptoms.
10 citations
,
July 2019 in “Indian Journal of Dermatology” Weekly azathioprine pulse is a better alternative to corticosteroids for treating alopecia areata due to fewer side effects.
5 citations
,
January 2022 in “PloS one” Deleting the p63 gene in certain cells causes problems in thymus development and severe hair loss in mice.
4 citations
,
February 2024 in “Anais Brasileiros de Dermatologia” 4 citations
,
March 2023 in “SKIN The Journal of Cutaneous Medicine” Hair regrowth improves quality of life and reduces anxiety and depression in severe alopecia areata patients.
3 citations
,
June 2023 in “Journal of dermatological treatment” Regrowing scalp hair improves quality of life and reduces anxiety and depression in severe alopecia areata patients.
3 citations
,
January 2021 in “Plastic and Aesthetic Research” Hair loss reduces hair thickness and coverage, but drug treatments mainly revive dormant hairs rather than reverse thinning; patients often undervalue their hair loss severity.
2 citations
,
October 2025 in “Frontiers in Medicine” Deuruxolitinib effectively improves hair regrowth in alopecia areata but requires monitoring for side effects.
2 citations
,
June 2025 in “Journal of Investigative Dermatology” 2 citations
,
June 2024 in “Journal of the American Academy of Dermatology” Patients and clinicians generally agree on eyebrow and eyelash hair loss improvements in severe alopecia areata.
1 citations
,
April 2025 in “Skin Health and Disease” Abrocitinib is being evaluated for safety and effectiveness in treating moderate to severe atopic dermatitis.